PAS

Digital Pathology Service Provider, HistoWiz, Expands Laboratory Footprint to Increase Capacity with New Headquarters in Queens

Retrieved on: 
Monday, March 20, 2023
Research, Science, Histology, Biotechnology, Collaboration, PAS, Pathology, Alexandria Center of Arts, Trichrome staining, Multimedia, H&E, ISH, Hospital, MD, In situ hybridization, Growth

Leading digital histology provider, HistoWiz, Inc. , opens a new 10,197 square foot central laboratory in Queens, New York inside the Alexandria Center for Life Science – Long Island City.

Key Points: 
  • Leading digital histology provider, HistoWiz, Inc. , opens a new 10,197 square foot central laboratory in Queens, New York inside the Alexandria Center for Life Science – Long Island City.
  • The HistoWiz laboratory facility houses the Company’s core histology services group including tissue processing, paraffin embedding, sectioning, and staining (H&E, Trichrome, PAS, etc.)
  • and will allow the Company to expand its capabilities in specialty services including immunofluorescence ( IF ) and in situ hybridization ( ISH ).
  • View the full release here: https://www.businesswire.com/news/home/20230320005063/en/
    HistoWiz's new histology lab in Long Island City will increase capacity and turnaround times for customers in biopharma research.

LG Display's 65-inch OLED TV Panel Received Carbon Footprint Certification from the Carbon Trust

Retrieved on: 
Sunday, March 19, 2023
Carbon, LG Display, Recycling, Carbon Trust, LCA, GxP, PAS, GHG, LCD, SGS, Greenhouse gas, MLA, OLED TV, Iron, OLED, Certification, Television

SEOUL, South Korea, March 18, 2023 /PRNewswire/ -- LG Display, the world's leading innovator of display technologies, announced today that its 65-inch OLED TV panel earned the Product Carbon Footprint Certification from the Carbon Trust.

Key Points: 
  • SEOUL, South Korea, March 18, 2023 /PRNewswire/ -- LG Display, the world's leading innovator of display technologies, announced today that its 65-inch OLED TV panel earned the Product Carbon Footprint Certification from the Carbon Trust.
  • With this achievement, the company's OLED panel further solidified the company's leadership in the OLED industry.
  • LG Display's 65-inch OLED panel received this recognition from the Carbon Trust by meeting the global standard (PAS 2050) on GHG (Greenhouse Gas) emissions throughout the entire product life cycle.
  • LG Display's OLED TV panel is also widely recognized for emitting the lowest blue light in the industry while providing users with the best flicker-free viewing experience.

Majesco P&C Policy Receives Top Recognition as a Dominant Provider in Aite-Novarica’s “Property/Casualty Policy Administration Systems” Report, 2023 Edition

Retrieved on: 
Thursday, March 9, 2023
Software, Technology, Professional Services, Insurance, General insurance, P&C, API, Growth, PAS, Software as a service, Partnership, Policy, Management, Majesco Entertainment

“The need for rapid product innovation, efficient operations, and robust digital capabilities is driving the need for core systems rich with APIs and accessible data.

Key Points: 
  • “The need for rapid product innovation, efficient operations, and robust digital capabilities is driving the need for core systems rich with APIs and accessible data.
  • “Majesco’s sizable customer base and continued momentum in the market qualifies them as a Dominant Provider in the P&C core systems space.”
    “We are delighted that Majesco Policy for P&C has been recognized as a dominant, leading provider by Aite-Novarica once again.
  • This recognition is a testament of the hard work and dedication of Majesco, as well as the success of our customers,” said Manish Shah, President and Chief Product Officer at Majesco.
  • Policy for P&C empowers carriers with agility, innovation, and speed while offering a lower risk model in terms of investment, operating costs, and scalability.

World Kidney Day: A Bayer Survey Reveals Physicians Agree on Need for Earlier Testing and Increased Transparent Communication for People Diagnosed With Chronic Kidney Disease Associated With Type 2 Diabetes

Retrieved on: 
Thursday, March 9, 2023
Cardiology, Biotechnology, Pharmaceutical, Managed Care, General Health, Health, Diabetes, Other Health, Advance for NPs & PAs, PCP, Diagnosis, Nephrology, Microalbuminuria, Kidney, CKD, Chronic kidney disease, T2D, Face, Partnership, NPS, Patient, Bayer, World Kidney Day, Guideline, Practitioner, PAS, Type 2 diabetes, Glomerular filtration rate, Pharmaceutical industry, Nursing, Cardiorenal syndrome

Today, World Kidney Day, results from a survey designed to gain a broader understanding of the attitudes and challenges faced by healthcare professionals (HCPs) in diagnosing, managing and treating people with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) were announced.

Key Points: 
  • Today, World Kidney Day, results from a survey designed to gain a broader understanding of the attitudes and challenges faced by healthcare professionals (HCPs) in diagnosing, managing and treating people with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) were announced.
  • The survey was executed by Bayer and fielded in partnership with MedSurvey, a leading medical market research company.
  • Findings from the survey, which queried a total of 1,000 respondents made up of nephrologists, primary care physicians (PCPs), nurse practitioners (NPs) and physician assistants (PAs), revealed that HCPs believe care can be improved, with a collective acknowledgement that people with T2D need to be tested for CKD earlier and more often, despite results showing that guideline-driven tests to monitor for CKD and its progression, like urine albumin-creatinine ratio (uACR), a urine test to assess kidney function, are underutilized.1,2
    When people are diagnosed with CKD associated with T2D, they often receive initial care from their PCP and are referred to a nephrologist (kidney specialists), only after their CKD has progressed.3
    Survey results also revealed that PCPs and nephrologists have differing opinions on who should be the lead medical professional coordinating treatment and management, resulting in a significant number of patients not being referred to nephrologists earlier, despite the majority of HCPs surveyed agreeing that nephrologists need to be brought in sooner.1
    “Research has shown that co-management between a primary care physician and a nephrologist is associated with improved quality of care, delayed dialysis and more frequent testing, but we wanted to more deeply understand some of the challenges the treatment team faced in an effort to incite conversations about how we can improve on them,” said German Guerrero, M.D., Executive Medical Director, Cardiorenal, Bayer.4 “At Bayer, we are working to ensure people with chronic kidney disease associated with type 2 diabetes receive optimal care that ultimately leads to earlier diagnosis and treatment and better outcomes.”
    The majority of HCPs surveyed (80% PCPs, 88% nephrologists, 88% NPs/PAs) agree the medical community could do better and diagnose CKD in people with T2D earlier1
    While a majority of HCPs are using estimated glomerular filtration rate (eGFR) blood tests to assess kidney function at least once every few months (62% PCPs, 80% nephrologists, 77% NPs/PAs), uACR tests are significantly underutilized (30% PCPs, 57% nephrologists, 38% NPs/PAs), clashing with guideline recommendations to test more frequently1
    The vast majority of HCPs (77% PCPs, 90% nephrologists, 89% NPs/PAs) agree nephrologists need to be brought in earlier, yet 88% of PCPs may choose not to refer people with CKD to a nephrologist; the top reasons include1:
    The top challenges HCPs face when co-managing patients include1:
    “These findings reinforce the importance of our commitment to identifying resources and programs aimed at better understanding the real-world management of chronic kidney disease and expanding screening and early care management,” said Dr. Guerrero.
  • “Together—with healthcare professionals and the broader kidney community—we have an opportunity to improve the diagnosis and management of chronic kidney disease to truly advance care.”

Vitech Solidifies Position as Industry Leader: Recognized as a Dominant Provider by Aite-Novarica Group for the Third Time

Retrieved on: 
Tuesday, March 7, 2023
Patient administration system, AWS, PAS, Vitech Corporation, Policy

NEW YORK, March 7, 2023 /PRNewswire/ -- Vitech Systems Group today announced its recognition as a Dominant Provider of Life/Annuity/Benefits Policy Administration Systems in Aite-Novarica Group's 2023 vendor analysis report.

Key Points: 
  • NEW YORK, March 7, 2023 /PRNewswire/ -- Vitech Systems Group today announced its recognition as a Dominant Provider of Life/Annuity/Benefits Policy Administration Systems in Aite-Novarica Group's 2023 vendor analysis report.
  • This marks Vitech's third consecutive time being recognized in the category.
  • "We are thrilled to be named a Dominant Provider by Aite-Novarica in its 2023 Life/Annuity/Benefits Policy Administration Systems Report for the U.S," said Richard Hart, CEO.
  • V3locity®, Vitech's cloud-native administration, engagement, and analytics platform offers complementary applications for full life cycle business functionality and enterprise capabilities.

RBC publishes 2022 Environmental, Social and Governance (ESG) Performance Report and Climate Report

Retrieved on: 
Monday, March 6, 2023
Legislation, Life, Social, Tax, Employment, Biophysical environment, Social Security Government Pension Offset, Royal Bank, PAS, Woman, Refinitiv, RBC, European Conservatives and Reformists Group Executive, ESG, Organic, Risk assessment, Climate change, Electricity, Royal Bank of Canada, University, Organization, Task force, BIPOC, Task Force on Climate Related Financial Disclosures, Management, Renewable energy, Cryptocurrency

Our 2022 Environmental, Social and Governance (ESG) Performance Report offers insights into RBC's approach to ESG and our 2022 performance across our key ESG strategic priorities and focus areas.

Key Points: 
  • Our 2022 Environmental, Social and Governance (ESG) Performance Report offers insights into RBC's approach to ESG and our 2022 performance across our key ESG strategic priorities and focus areas.
  • Our 2022 Climate Report summarizes RBC's progress in advancing how we manage climate-related risks and opportunities in line with our enterprise climate strategy, the RBC Climate Blueprint and in implementing the recommendations of the Task Force on Climate-related Financial Disclosures.
  • At RBC, we're proud to play our part as we demonstrate and measure our progress to hold ourselves accountable.
  • The climate modifier outlined in the 2022 Climate Report gives the board flexibility to make modifications to executives' Mid-Term Incentive and Long-Term Incentive awards, taking into consideration their actions supporting our climate strategy.

Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update

Retrieved on: 
Tuesday, February 28, 2023
Biotechnology, Health, Cosmetics, Retail, Pharmaceutical, Marketing, Clinical trial, PDUFA, Depreciation, Therapy, Prescription Drug User Fee Act, ID, SG, Filler (linguistics), GPV, MD, Krause, Senior, Amgen, MBA, RHA, Research, Torticollis, Partnership, GAAP, Drug discovery, Webcast, FDA, Investment, R, Growth, Human resources, PAS, OPEX, Video game, Pharmaceutical industry, Cryptocurrency, Management

Revance Therapeutics, Inc. (RVNC), today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • Revance Therapeutics, Inc. (RVNC), today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.
  • Excluding depreciation, amortization and stock-based compensation, non-GAAP SG&A expenses were $55.5 million and $183.1 million, respectively, for the fourth quarter and full year ended December 31, 2022.
  • Excluding depreciation, amortization and stock-based compensation, non-GAAP R&D expenses were $17.3 million and $83.9 million, respectively, for the fourth quarter and full year ended December 31, 2022.
  • Excluding cost of revenue, depreciation, amortization, stock-based compensation, and impairment charge, non-GAAP OPEX were $72.8 million for the fourth quarter ended December 31, 2022.

Cancer Advances, Inc. Announces Issuance of New U.S. Patent

Retrieved on: 
Tuesday, February 28, 2023
Cancer, Survival, Fibrosis, Pancreatic cancer, Gastrointestinal cancer, Research, Neoplasm, Patient, Patent, Therapy, PAS, GI, Tumor microenvironment, Antibody, Humoral immunity, Pharmaceutical industry, Gastrin

DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, announced that the U.S. Patent and Trademark Office has issued new patent No.

Key Points: 
  • DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, announced that the U.S. Patent and Trademark Office has issued new patent No.
  • The new patent titled “Compositions and Methods for Inducing Humoral and Cellular Immunities against Tumors and Cancer” covers a method for treating and/or preventing and/or inhibiting development of a tumor and/or a cancer associated with gastrin signaling in a subject.
  • The novel IP further covers methods for treatment of GI cancer by administering PAS followed by an immune checkpoint inhibitor.
  • Cancer Advances plans to seek approval for PAS in the treatment of gastric and pancreatic cancers.

Origami Risk Gains Momentum in New Aite-Novarica Report on P&C Policy Administration Systems

Retrieved on: 
Monday, February 27, 2023
Software, Insurance, Networks, Consulting, Data Management, Professional Services, Technology, Security, Origami, Cloud, Safety, Software as a service, P&C, Policy, Maintenance, ISO, Research, Database, Unified, Growth, MGA, PAS, NCCI, TPA, Risk management, Video game, Risk

The new Aite-Novarica Property/Casualty Policy Administration Systems Report (compiled in February) groups Origami among “contenders,” a designation for providers with “substantial customer experience and momentum.” Origami Risk’s policy administration solution moved to the “contender” category from its position in the “new entrant” category in the previous (2021) report.

Key Points: 
  • The new Aite-Novarica Property/Casualty Policy Administration Systems Report (compiled in February) groups Origami among “contenders,” a designation for providers with “substantial customer experience and momentum.” Origami Risk’s policy administration solution moved to the “contender” category from its position in the “new entrant” category in the previous (2021) report.
  • This reflects the growth of Origami Risk’s P/C insurer client base and expanding market presence in the insurance industry.
  • According to the Aite-Novarica Group, the report provides an overview of the property and casualty (P/C) policy administration solution (PAS) market.
  • To read Origami’s review and profile in the Aite-Novarica P/C Policy Administration Report, visit: https://www.origamirisk.com/resources/industry-reports/aite-novarica-rep... .

ThriveAP and the American Academy of Emergency Nurse Practitioners Announce Strategic Partnership for Transition to Practice

Retrieved on: 
Monday, February 27, 2023
App, Organization, Partnership, Urgent care center, Patient, Emergency medicine, PAS, Practitioner, NPS, Education, American Academy, Nursing, Hospital

NASHVILLE, Tenn., Feb. 27, 2023 /PRNewswire-PRWeb/ -- ThriveAP and the American Academy of Emergency Nurse Practitioners (AAENP) are proud to announce their strategic partnership supporting post-graduate transition to practice for APPs.

Key Points: 
  • ThriveAP and the American Academy of Emergency Nurse Practitioners (AAENP) are proud to announce their strategic partnership supporting post-graduate transition to practice for APPs.
  • NASHVILLE, Tenn., Feb. 27, 2023 /PRNewswire-PRWeb/ -- ThriveAP and the American Academy of Emergency Nurse Practitioners (AAENP) are proud to announce their strategic partnership supporting post-graduate transition to practice for APPs.
  • This partnership agreement represents a major milestone for advanced practice providers (APPs), as ThriveAP is the leading transition to practice education solution for APPs, and the AAENP is the preeminent specialty organization for nurse practitioners in emergency care.
  • By combining ThriveAP's high-quality and comprehensive transition to practice education with AAENP's expertise in emergency care, this strategic partnership will equip APPs with the necessary skills and knowledge to excel in the delivery of urgent and emergency care.